Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer. (Q42745161)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21430399%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

title

Molecular subtypes and tumor response to neoadjuvant chemotherapy in patients with locally advanced breast cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21430399%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21430399%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Ja Seung Koo

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21430399%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

author name string

Seung Il Kim

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21430399%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Se Ho Park

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21430399%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Hyung Seok Park

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21430399%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

Byeong Woo Park

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21430399%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

publication date

1 January 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21430399%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21430399%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

volume

79

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21430399%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

issue

5-6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21430399%20AND%20SRC:MED&resulttype=core&format=json

26 January 2020

page(s)

324-330

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21430399%20AND%20SRC:MED&resulttype=core&format=json

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006.

26 January 2020

cites work

1 reference

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

21 January 2018

1 reference

Molecular portraits of human breast tumours

21 January 2018

1 reference

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

21 January 2018

1 reference

Repeated observation of breast tumor subtypes in independent gene expression data sets

21 January 2018

1 reference

Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial.

21 January 2018

1 reference

Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype

21 January 2018

1 reference

Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma

21 January 2018

1 reference

The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes

21 January 2018

1 reference

Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update.

21 January 2018

1 reference

Breast cancer molecular subtypes respond differently to preoperative chemotherapy

21 January 2018

1 reference

Weekly paclitaxel improves pathologic complete remission in operable breast cancer when compared with paclitaxel once every 3 weeks

21 January 2018

1 reference

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer

21 January 2018

1 reference

Primary systemic therapy in operable breast cancer: clinical data and biological fall-out

21 January 2018

1 reference

Evaluation of ER, PgR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer

21 January 2018

1 reference

Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy

21 January 2018

1 reference

Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases

21 January 2018

1 reference

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer

21 January 2018

1 reference

Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer

21 January 2018

1 reference

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

21 January 2018

1 reference

Neoadjuvant therapy with paclitaxel followed by 5-fluorouracil, epirubicin, and cyclophosphamide chemotherapy and concurrent trastuzumab in human epidermal growth factor receptor 2-positive operable breast cancer: an update of the initial randomized

21 January 2018

1 reference

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

21 January 2018

1 reference

BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells

21 January 2018

1 reference

Selective induction of chemotherapy resistance of mammary tumors in a conditional mouse model for hereditary breast cancer

21 January 2018

1 reference

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

21 January 2018

1 reference

High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs

21 January 2018

1 reference

Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel

21 January 2018

1 reference

In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer: the GEPARTRIO pilot study.

21 January 2018

1 reference

Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer

21 January 2018

1 reference

Ki67 expression and docetaxel efficacy in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

21 January 2018

1 reference